n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Visiongain has published a new report titled Clinical Trial Supplies Market Report 2024-2034: Forecasting by Location (Offshore Clinical Site, National Clinical Site), Through Type (Small Molecule Products, Biologics, Medical Devices), Through Services (Manufacturing (Trials & Testing). Kits, Investigational New Drugs (IMP) and INDs (Investigational New Drugs), Placebos, Others), Packaging & Labeling, Logistics & Distribution (Cold Chain Distribution, Non-Cold Chain Distribution), Garage & Retention, by Comparison, Others), through Healing Spaces (Oncology, CNS & Intellectual Disorders, Cardiovascular Diseases (CVD), Infectious Diseases, Immune Diseases, Blood Disorders, Metabolic Disorders, digestive disorders, others)), going through the phase (Phase I, Phase II, Phase III, Phase IV), through end-users (pharmaceutical and biotech corporations, contract research organizations, medical device companies, others) and leading market analysis at the regional and national level, PLUS analysis of key companies AND analysis of the COVID-19 recovery and impact model.
The clinical trial materials market is estimated at US$4,146. 7 billion in 2024 and is expected to grow at a CAGR of 8. 8% during the forecasted period, 2024-2034.
Increasing Demand for Biologics is Driving Market Growth
The proliferation of clinical trials with biologics and temperature-sensitive drugs has stimulated the demand for specialized services under the bloodless chain to ensure product integrity and efficacy. Monoclonal antibodies such as trastuzumab (Herceptin) and Rituximab (Rituxan), as well as insulin. and erythropoietin biologics (EPO), highlight the increasing use of complex molecular treatments to address a variety of medical needs. Tumor necrosis (TNF) inhibitors, such as adalimumab (Humira), further underscore this trend in the treatment of autoimmune diseases. In November 2023, Sanofi and Regeneron announced promising interim effects from the phase III NOTUS trial with Dupixent (dupilumab), demonstrating a significant reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). This expansion of the bloodless chain sources market is primarily driven by the imperative of accurate temperature control in the source chain, which is critical for biologics, the addition of vaccines, and monoclonal antibodies.
Download a https://www. visiongain. com/report/clinical-trial-supplies-market-2024/#download_sampe_div Pattern Report
How has COVID-19 had a significant impact on the clinical trial materials market?
The COVID-19 pandemic has particularly reshaped the chain of origin of clinical trials, taking operations from preclinical stages to knowledge analysis. One of the main points contributing to this disruption is the lack of a comprehensive call for proposals for the development of forecasting and feasibility plans. In addition, adjustments in regional regulations and regulatory frameworks are prepared for the importation of control materials. To address those challenges, pharmaceutical corporations are taking collaborative approaches to securing testing materials and diversifying their supplier networks. Participating in collaborative chain-of-origin schemes allows sponsors to maintain flexibility at origin, access real-time stock market information, and, as it should, request forecasts. In addition, diversifying the supplier base is helping to mitigate the negative effects of macroeconomic fluctuations. Also, as a reaction to COVID-19, there is a global shift towards decentralization. Clinical trial models to improve patient retention rates.
What will this report look like for you?
Visiongain’s 373-page report contains 155 tables and 243 tables/graphs. Our new study is suitable for anyone who wants in-depth commercial research of the clinical trial materials market, as well as detailed research of market segments. Our new study will help you evaluate the global and regional clinical trial materials market. Get monetary research of the general market and other segments, adding the scale of operation, contract manufacturer size, stem mobile source, stem mobile type, and end-user, and capture a superior market share. There are great opportunities in this rapidly developing market for clinical trial materials. Learn how to use existing and future opportunities in this market to generate profits in the near future. In addition, the report will help you improve your strategic decision-making, allowing you to outline expansion strategies, strengthen research on other market players, and maximize the company’s productivity.
What are the drivers of the existing market?
Increased investment in the production of new pharmaceuticals.
Growing investments and partnerships by primary pharmaceutical corporations are driving the economic expansion of the clinical trial materials market. For example, in December 2022, Merck and Kelun-Biotech signed an exclusive partnership and license agreement to expand seven investigational preclinical antibody-drug conjugates (ADCs) for cancer treatment, with Merck providing an upfront payment of 175 million of dollars. at Kelun-Biotech. Additionally, Kelun-Biotech is expected to achieve historic long-term invoices of up to $9. 3 billion if the ADCs gain regulatory approval, as well as tiered royalties on net sales of any commercialized ADC products. These expanding investments are driving the demand for essential facilities such as distribution chain, warehousing, packaging, labeling and sourcing of bloodless comparators, especially changing the profit expansion of the clinical trial materials market. For example, Catalent recently invested $9 million in a new clinical resource center in San Diego to spruce up its early-stage clinical testing facilities. Additionally, to expand its presence in expanding regions, Biocair has partnered with Linehaul Express in India, paving the way for higher quality clinical trial materials and revenue expansion opportunities in the market.
Technological Advancements Are Driving Market Expansion
The clinical trial landscape in the pharmaceutical and biotechnology industries is transforming due to the integration of new technological advances and the emergence of online communities. There is a notable trend toward outsourcing as corporations seek to take advantage of those innovations. Artificial intelligence (AI) and complex software solutions are widely deployed to address source chain challenges, minimize waste and costs, accelerate time to market, temporarily initiate new trials, manage plan production , optimize ongoing testing methods and facilitate the launch of ads. Sanofi, a major player in the pharmaceutical and healthcare industry, partnered with N-SIDE five years ago to modernize its clinical origin chain processes, resulting in significant improvements in potency. For example, N-SIDE uses extensive experience in clinical source chains and complex mathematical techniques to comprehensively optimize test source chains. By taking a global mindset and data-driven decision making at every step, N-SIDE enables pharmaceutical corporations of all sizes to manage their clinical trial operations well. Additionally, Controlant’s Aurora platform revolutionizes distribution across the entire clinical trial origination chain, offering real-time visibility down to the individual product level. This cutting-edge technique is already being applied across primary pharmaceutical corporations, highlighting its effectiveness in streamlining distribution processes.
Get a detailed ToC https://www. visiongain. com/report/clinical-trial-supplies-market-2024/
Where are the market opportunities?
The Expansion of Emerging Economies and the Prioritization of R
Singapore, Brazil, Russia, India, China, South Africa, Mexico, South Korea, Indonesia and Turkey are vital emerging markets in the clinical trial materials sector; Sales of pharmaceutical products have quadrupled in five years to capture 20% of the world market. pharmaceutical market. walk. This shift toward emerging markets is attributed to their gigantic populations, growing sources of income, and increasing life expectancy, amid stagnant expansion and expired patents in established countries. Singapore has become a leading hub for research, biopharmaceutical production and advertising activities in the Asia-Pacific region, thanks to government support, a thriving startup ecosystem and a physically powerful infrastructure. Large pharmaceutical players such as GlaxoSmithKline, Novartis, Pfizer and Sanofi have been attracted to Singapore’s business-friendly environment and highly professional workforce. Over the past two decades, Singapore has seen a notable rise in its biopharmaceutical exports, reaching S$19 billion (US$14. 27 billion) in 2022, demonstrating the super-expansion of the sector. This expansion is further enhanced by the influx of Chinese companies setting up shop in Singapore. In particular, WuXi Biologics, a Chinese company specializing in the production of raw materials for the AstraZeneca COVID-19 vaccine, declared in August last year its goal of investing $1. 4 billion over the next decade in creating a research facility. and production. . In Singapore.
Collaboration and alliances, key actors
Collaboration and partnerships within the clinical trial materials industry are key to achieving better patient outcomes and driving market growth. By aligning with healthcare providers, brands gain very important insights, refine device design, and ensure seamless integration within healthcare systems. The collaborations come with Pfizer’s adoption of Snowflake in June 2023 to revolutionize clinical trials through robotics and automation. Similarly, Ariceum Therapeutics and Eurofins CDMO partnered in June 2023 for the acquisition of clinical trials of Array, while ICON plc collaborated with BARDA for source control in September 2023. In addition, Movianto’s logistics agreement with Theramex in February 2023 highlights the importance of logistics partnerships for effective sourcing. Chain management in clinical trials.
Competitive Landscape
The market for clinical trial materials is characterized by a high degree of fragmentation, with many corporations and products. In 2023, key players such as Biocair, Bionical Limited, Catalent Inc. , Eurofins Scientific SE, ICON plc, IQVIA Holdings Inc. , KLIFO, Lonza Group AG, Marken, Parexel International, PCI Pharma Services, Sharp Services, LLC, Thermo Fisher Scientific Inc. , Walden Group SAS account for the largest percentage of profits in the global clinical trial materials market. To decorate their positions in the market, those industry leaders have implemented a diversity of methods by adding mergers and acquisitions, really significant investments in studies and development, collaborative projects, partnerships, regional expansions and the arrival of cutting-edge products.
RECENT DEVELOPMENTS
In June 2023, Pfizer implemented Snowflake on patient outcomes, revolutionized clinical trials through robotics and automation, and performed predictive analytics for diagnosis and chain-of-origin monitoring.
In June 2023, Ariceum Therapeutics (Ariceum) and Eurofins CDMO announced a strategic partnership. This collaboration comes as Eurofins CDMO provides clinical trial facilities for Ariceum’s ongoing Phase I/II clinical studies in Australia, as well as upcoming clinical trials.
In September 2023, ICON plc partnered with BARDA to conduct clinical trials by adding management.
To learn about the contents of this document, please send an email to contactus@visiongain. com. Don’t miss a thing by staying informed – request our report now.
For more reports of Visiongain studies on the pharmaceutical sector, click on the links below:
Pharmaceutical Clinical Trial Services Market Report 2024-2034
Clinical Trial Logistics and Procurement Market for the Pharmaceutical Industry 2023-2033
Clinical Trial Support Services Market Report 2023-2033
Do you have a traditional need that we can meet? Do you want express data about a country, geographic region, market segment or express company?Contact us today, we can talk about your wishes and see how we can: contactus@visiongain . com
About VisionGain
Visiongain is one of the fastest-growing and most advanced independent business information providers on the market. The company publishes a large number of market research reports that it adds to its extensive portfolio every year. These reports provide in-depth studies of 18 sectors around the world. The reports, which cover 10-year forecasts, are many pages long, with detailed market studies and valuable competitive intelligence data. Visiongain works in a diversity of verticals with many synergies. These markets come with automotive, aviation, chemical, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmaceuticals, and utilities. Our syndicated and customized market research reports offer market intelligence tailored to your business needs.
Contact
Visiongain Reports Limited Phone: (0) 20 7336 6100 Email: contactus@visiongain. com Web: www. visiongain. com